|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.25 - 12:36
|
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights (Business Wire)
|
|
|
Highlights:
6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June
Phase 3 COMP006 in TRD on track for 26-week data second half of 2026
Cash position of $260.1 million at March 31, 2025
Conference call on May 8 at 8:00 am ET (1:00 pm UK)
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business.
“We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir Nath, Chief Executive Officer. “Our continued progress reinforces Compass' leadership in psychedelic therapy development, which we believe represents the next generation of mental health therapeutic o...
|
|
|
28.04.25 - 12:36
|
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 (Business Wire)
|
|
|
Compass management will host a conference call at 8:00 am ET (1:00 pm UK)
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025.
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025.
A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We...
|
|
|
|
|
|
|
|
|
|
|
|
|
27.02.25 - 12:33
|
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights (Business Wire)
|
|
|
Highlights:
Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025
Phase 3 COMP006 in TRD is on track for 26-week data in second half of 2026
Cash position of $165.1 million at December 31, 2024; additional $150 million gross cash proceeds raised in January 2025
Conference call on February 27 at 8:00 am ET (1:00 pm UK)
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provided an update on recent progress across its business.
“We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with top-line 6-week data expected next quarter,” said Kabir Nath, Chief Executive Officer. “Building on last year's promising phase...
|
|
|
18.02.25 - 12:36
|
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025 (Business Wire)
|
|
|
Compass management will host a conference call at 8:00 am ET (1:00pm UK)
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025.
Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on the Compass Pathways website at: Fourth Quarter 2024 Financial Results
The webcast will also be available on the Investors section of Compass Pathways website. The webcast will be archived for 30 days.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to acce...
|
|
|
21.01.25 - 12:33
|
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer (Business Wire)
|
|
|
Newly created role of Chief Patient Officer reinforces Compass' vision of working to achieve broad and equitable access to COMP360, if approvedLONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by the company are focused on addressing unmet needs in current clinical care and are designed to improve patient outcomes.
“Steve has spent the past four years working to deeply understand barriers to care for patients living with serious mental health conditions and he is committed to helping find solutions to address those barriers,” said Kabir Nath,...
|
|
|
|
|
10.01.25 - 13:03
|
Compass Pathways Announces Pricing of Underwritten Offering (Business Wire)
|
|
|
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions.
The offering was led by Deep T...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
